Restoration of Epigenetically Silenced Sulfatase 1 Expression by 5-Aza-2′-Deoxycytidine Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy-Induced Apoptosis

Background: Hepatocellular carcinoma (HCC) is the second most frequent cause of cancer death worldwide. Sulfatase 1 (SULF1) functions as a tumor suppressor in HCC cell lines in vitro but also has an oncogenic effect in some HCCs in vivo. Aim: The purpose of this study was to examine the mechanisms regulating SULF1 and its function in HCC. Methods: First, SULF1 mRNA and protein expression were examined. Second, we examined SULF1 gene copy numbers in HCC cells. Third, we assessed whether DNA methylation or methylation and/or acetylation of histone marks on the promoter regulate SULF1 expression. Finally, we examined the effect of 5-aza-2′-deoxycytidine (5-Aza-dC) on sulfatase activity and drug-induced apoptosis. Results: SULF1 mRNA was downregulated in nine of eleven HCC cell lines, but only in six of ten primary tumors. SULF1 mRNA correlated with protein expression. Gene copy number assessment by fluorescence in situ hybridization showed intact SULF1 alleles in low-SULF1-expressing cell lines. CpG island methylation in the SULF1 promoter and two downstream CpG islands did not show an inverse correlation between DNA methylation and SULF1 expression. However, chromatin immunoprecipitation showed that the SULF1 promoter acquires a silenced chromatin state in low-SULF1-expressing cells through an increase in di/trimethyl-K9H3 and trimethyl-K27H3 and a concomitant loss of activating acetyl K9, K14H3 marks. 5-Aza-dC restored SULF1 mRNA expression in SULF1-negative cell lines, with an associated increase in sulfatase activity and sensitization of HCC cells to cisplatin-induced apoptosis. Conclusion: SULF1 gene silencing in HCC occurs through histone modifications on the SULF1 promoter. Restoration of SULF1 mRNA expression by 5-Aza-dC sensitized HCC cells to drug-induced apoptosis.

[1]  C. Moser,et al.  Activation of the transforming growth factor‐β/SMAD transcriptional pathway underlies a novel tumor‐promoting role of sulfatase 1 in hepatocellular carcinoma , 2015, Hepatology.

[2]  V. Santini,et al.  Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3 , 2013, Epigenetics.

[3]  B. Ren,et al.  Genome organization and long-range regulation of gene expression by enhancers. , 2013, Current opinion in cell biology.

[4]  Antoine H. F. M. Peters,et al.  H3K9/HP1 and Polycomb: two key epigenetic silencing pathways for gene regulation and embryo development. , 2013, Current topics in developmental biology.

[5]  A. Goel,et al.  Up‐regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer , 2012, The Journal of pathology.

[6]  C. Chenu,et al.  Mammalian Sulf1 RNA alternative splicing and its significance to tumour growth regulation , 2012, Tumor Biology.

[7]  H. Nagase,et al.  Genome-wide survey reveals dynamic widespread tissue-specific changes in DNA methylation during development , 2011, BMC Genomics.

[8]  S. Lemon,et al.  Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer , 2011, Oncogene.

[9]  J. Chien,et al.  HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. , 2011, Cancer research.

[10]  Chunling Hu,et al.  Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor phenotypes, and survival , 2011, Genes, chromosomes & cancer.

[11]  G. Mills,et al.  Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer , 2011, Journal of experimental & clinical cancer research : CR.

[12]  B. Klein,et al.  SULFs in human neoplasia: implication as progression and prognosis factors , 2011, Journal of Translational Medicine.

[13]  T. Dragani,et al.  Risk of HCC: genetic heterogeneity and complex genetics. , 2010, Journal of hepatology.

[14]  S. Chanock,et al.  Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer , 2010, PloS one.

[15]  Koichi Hirata,et al.  Gene expression analysis identifies over‐expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer , 2010, Genes, chromosomes & cancer.

[16]  R. Chung,et al.  Viral hepatocarcinogenesis , 2010, Oncogene.

[17]  S. Sanderson,et al.  Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. , 2009, Journal of hepatology.

[18]  S. Kalloger,et al.  Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. , 2009, Cancer research.

[19]  Hai-Meng Zhou,et al.  Promoter hypermethylation correlates with the Hsulf‐1 silencing in human breast and gastric cancer , 2009, International journal of cancer.

[20]  Tara L. Kieffer,et al.  Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .

[21]  L. Roberts,et al.  Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. , 2008, Future oncology.

[22]  Dawn R. Chin,et al.  Transforming Growth Factor-β1 Induces Heparan Sulfate 6-O-Endosulfatase 1 Expression in Vitro and in Vivo* , 2008, Journal of Biological Chemistry.

[23]  S. Thorgeirsson,et al.  Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma , 2008, Hepatology.

[24]  H. El‐Serag Epidemiology of hepatocellular carcinoma in USA , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  J. Chien,et al.  Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance , 2007, Oncogene.

[26]  S. Pradhan,et al.  Functional cooperation between HP1 and DNMT1 mediates gene silencing. , 2007, Genes & development.

[27]  J. Chien,et al.  Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer* , 2007, Journal of Biological Chemistry.

[28]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[29]  J. Chien,et al.  HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. , 2006, Cancer research.

[30]  Chunrong Yu,et al.  SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. , 2006, Gastroenterology.

[31]  S. Sanche,et al.  5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. , 2006, Leukemia research.

[32]  M. Thomas,et al.  Opportunities for targeted therapies in hepatocellular carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Friess,et al.  Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer , 2005, Molecular Cancer.

[34]  B. Dörken,et al.  Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms , 2005, Leukemia.

[35]  David I. Smith,et al.  HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma , 2004, Oncogene.

[36]  David I. Smith,et al.  hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. , 2004, Gastroenterology.

[37]  David I. Smith,et al.  Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer* , 2003, Journal of Biological Chemistry.

[38]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[39]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[40]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[41]  S. Cross,et al.  Purification of CpG islands using a methylated DNA binding column , 1994, Nature Genetics.